Investigation of new agents in small-cell lung cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.

Original languageEnglish (US)
JournalChest
Volume103
Issue number4 SUPPL.
StatePublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Patient Selection
Research Personnel
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Investigation of new agents in small-cell lung cancer. / Johnson, D. H.

In: Chest, Vol. 103, No. 4 SUPPL., 1993.

Research output: Contribution to journalArticle

@article{63d033aac3f043f2982d0c78b13fcef9,
title = "Investigation of new agents in small-cell lung cancer",
abstract = "The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.",
author = "Johnson, {D. H.}",
year = "1993",
language = "English (US)",
volume = "103",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Investigation of new agents in small-cell lung cancer

AU - Johnson, D. H.

PY - 1993

Y1 - 1993

N2 - The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.

AB - The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.

UR - http://www.scopus.com/inward/record.url?scp=0027412660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027412660&partnerID=8YFLogxK

M3 - Article

VL - 103

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL.

ER -